Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20032440
PII: 29/11/4813
Knihovny.cz E-resources
- MeSH
- alpha-Tocopherol blood MeSH
- Atherosclerosis blood chemically induced MeSH
- Bevacizumab MeSH
- Cholesterol blood MeSH
- Adult MeSH
- Fluorouracil administration & dosage adverse effects MeSH
- Glycated Hemoglobin metabolism MeSH
- Homocysteine blood MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Colorectal Neoplasms blood drug therapy MeSH
- Leucovorin administration & dosage adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Antibodies, Monoclonal administration & dosage adverse effects MeSH
- Organoplatinum Compounds administration & dosage adverse effects MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage adverse effects therapeutic use MeSH
- Aged MeSH
- Vitamin A blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- alpha-Tocopherol MeSH
- Bevacizumab MeSH
- Cholesterol MeSH
- Fluorouracil MeSH
- Glycated Hemoglobin A MeSH
- Homocysteine MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Leucovorin MeSH
- Antibodies, Monoclonal MeSH
- Organoplatinum Compounds MeSH
- Vitamin A MeSH
BACKGROUND: Targeted agents present with a new spectrum of side-effects, including toxicities that negatively impact the risk of atherosclerosis. The aim of the present study was to evaluate the effect of the combination of targeted therapy and chemotherapy on serum homocysteine and other laboratory parameters of cardiovascular risk in patients with metastatic colorectal carcinoma. PATIENTS AND METHODS: Thirty-one patients with metastatic colorectal carcinoma treated with the combination of bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin were studied before and during the therapy. RESULTS: Serum homocysteine decreased significantly throughout the course of treatment. Total cholesterol and low-density lipoprotein cholesterol also decreased significantly during the first month of therapy. In contrast, serum retinol significantly increased during the second and third months of treatment. A significant increase in glycosylated hemoglobin was also observed. After an initial rise, serum C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were significantly lower compared to baseline throughout the course of treatment. Serum ferritin increased throughout most of the course of treatment. A significant correlation was observed between CRP and high-density lipoprotein cholesterol, retinol, ferritin, and CEA. CEA correlated with hemoglobin, retinol, and ferritin. Retinol correlated significantly with hemoglobin. CONCLUSION: Tumor control, reflected in lower CEA, resulted in suppression of the acute phase response and generally in favorable effects on laboratory parameters indicative of risk factors of atherosclerosis, including lower homocysteine concentrations, and lower total and LDL cholesterol.
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
